Objective:To compare the efficacy and safety of Taitacept and Beliuzumab in the treatment of patients with lupus nephritis(LN).Methods:A total of 120 patients with LN admitted to Shouguang People's Hospital from April 2022 to June 2024 were selected as the research objects,and divided into a group A and a group B by random number table method,with 60 cases in each group.Both groups were treated on the basis of the clinical standard treatment regimen,group A was treated with Taitacept and group B was treated with Beliuzumab.The immune function,renal function and complications were compared between the two groups.Results:After treatment,the levels of immunoglobulin(Ig)A,IgG and IgM in both groups were lower than before treatment,the levels of complement C3 and C4 in group A were higher than before treatment,and the levels of complement C4 in group A were higher than that in group B,with statistical significance(P<0.05).After treatment,24 h urinary protein quantity,serum creatinine and blood urea nitrogen levels in two groups were lower than before treatment,group A was lower than group B,with statistical significance(P<0.05).The incidence of complications in group A was 21.67%,which was higher than 6.67%in group B,the difference was statistically significant(P<0.05).Conclusion:Titacept has better performance in reducing immunoglobulin level,increasing complement level and improving renal function,but the safety issue still needs further attention.
维普
万方数据